Management of Low-Stage Testicular Seminoma

Pearce, Shane M.; Liauw, Stanley L.; Eggener, Scott E.

doi:10.1016/j.ucl.2015.04.003

Cited by 10 publications

(9 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the dose and field of radiation was reduced over the past 20 years to 20 gy administered in 10 daily 2.0 fractions to para-aortic and/or ipsilateral iliac lymph nodes, adjuvant radiotherapy in stage i seminoma has been abandoned in many major medical centers because of the long term risk of secondary malignancies and cardiovascular toxicity 1,2 . Adjuvant chemotherapy with 1-2 cycles of carboplatin dosed at the AuC of 7 did not improve overall survival and due to added toxicity it is not the first option for patients who are willing to undergo surveillance program 9,15 .…”

Section: Seminoma Stage Imentioning

confidence: 99%

“…stage ii is defined as a tumor that involves testis and retroperitoneal lymph nodes, without visceral metastases and with normal or raised postorchiectomy serum tumor markers at primary diagnosis. About 15% to 20% of patients diagnosed with seminoma are classified as having stage ii disease 15 . Postorchiectomy treatment options for stage ii seminoma include radiotherapy to para-aortic and ipsilateral iliac lymph nodes to the cumulative dose of 30-36 gy, multi agent cisplatin based chemotherapy with 3 cycles of cisplatin, etoposide and bleomycin protocol (PeB protocol) or 4 cycles of cisplatin, etoposide protocol (Pe protocol).…”

Section: Seminoma Stage IImentioning

confidence: 99%

See 1 more Smart Citation

Treatment of Germ Cell Testicular Cancer

Kunac

Gnjidić

Golubić

et al. 2020

ACC

View full text Add to dashboard Cite

germ cell testicular cancer (gCTC) is a malignant neoplasm derived from the primordial germ cell. Although it accounts for approximately 1% of all malignancies in men, it is the most common cancer of younger male population, with the highest incidence between ages 15 and 35. Testicular cancer incidence rate has risen globally over the past several decades, with the average increase in the incidence of testicular cancer in Croatia of 7% per annum from the year 1983 to 2007. Two main groups are seminomas and non-seminomas, each accounting for 50% of cases, and they differ in treatment modalities and response to therapy. Despite increase in the incidence rate, a promising circumstance is that gCTC has become a model of curable cancer. Because of advances in diagnostic procedures, sophisticated radiation techniques and especially the introduction of cisplatin based chemotherapy protocols together with advanced postchemotherapy surgical techniques, curability is expected in about 95% of all patients diagnosed with testicular cancer and over 70% of patients with advanced disease. in this review, we will focus on treatment strategies of primary gCTC.

show abstract

Section: Seminoma Stage Imentioning

confidence: 99%

Section: Seminoma Stage IImentioning

confidence: 99%

Treatment of Germ Cell Testicular Cancer

Kunac

Gnjidić

Golubić

et al. 2020

ACC

View full text Add to dashboard Cite

show abstract

“…2,3,4 Adjuvantna monokemoterapija karboplatinom (AUC = 7) provodi se u 1 (IB) ili 2 ciklusa. 2,6,7 Alternativno se može aplicirati fiksna doza adjuvantne karboplatine od 400 mg/m 2 .…”

Section: Stadiji Ia I Ibunclassified

Clinical guidelines for diagnostics, treatment and monitoring of patients with testicular cancer

Gamulin

Bulimbašić

Jazvić

et al. 2019

View full text Add to dashboard Cite

“…Seminoma accounts for more than half of testicular germ cell tumors (GCTs), with peak incidence at 35 to 45 years of age 1,2 . New Zealand Ministry of Health data from 2005 to 2017 show that Maori men have consistently higher rates of testicular cancer than non‐Maori men 3 .…”

Section: Introductionmentioning

confidence: 99%

Two cycles of adjuvant carboplatin for clinical stage 1 testicular seminoma in New Zealand centres: A retrospective analysis of efficacy and long‐term events

et al. 2020

View full text Add to dashboard Cite

Background Adjuvant carboplatin reduces relapse risk in clinical stage 1 (CS1) seminoma, though there is a paucity of long‐term safety data. Aim Our objective was to report long‐term outcomes of two cycles of adjuvant carboplatin dosed at area under the time–concentration curve (AUC) of 7. Methods and results We performed a retrospective analysis on treatment and outcomes of patients with CS1 seminoma who received adjuvant carboplatin from 2000 to 2016 at our centres in the Midland Region, New Zealand. Of 159 patients, median age 39 years, 153 received two cycles of carboplatin: 147 dosed at AUC7 and 6 at AUC6. Six patients had one cycle of carboplatin AUC7. One patient relapsed at 22 months and died of bleomycin pneumonitis 2 months after achieving a complete response with BEP chemotherapy. Neither RTI (present in 21.3%) nor tumor size >4 cm (in 43.3%) was predictive of relapse. Median follow‐up was 106 months. At 15 years, outcomes were: relapse‐free survival 99.4%, overall survival 91.4%, disease‐specific survival 100%, subsequent malignant neoplasm rate 7.6%, and second testicular germ cell tumor rate 3.85%. One patient had persistent grade 1 thrombocytopenia at 46 months. Conclusions These data add to the body of evidence that two cycles of carboplatin AUC7 is safe and effective adjuvant treatment for CS1 seminoma.

show abstract

Management of Low-Stage Testicular Seminoma

Cited by 10 publications

References 101 publications

Treatment of Germ Cell Testicular Cancer

Treatment of Germ Cell Testicular Cancer

Clinical guidelines for diagnostics, treatment and monitoring of patients with testicular cancer

Two cycles of adjuvant carboplatin for clinical stage 1 testicular seminoma in New Zealand centres: A retrospective analysis of efficacy and long‐term events

Contact Info

Product

Resources

About